Aripiprazole Wet Granulation Drying
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Aripiprazole's hygroscopic nature leads to polymorphic transformations during pharmaceutical composition preparation, reducing bioavailability and solubility, and existing wet granulation methods are inefficient and costly due to moisture sensitivity.
Innovation Solution
A method of wet granulation involving a mixture of aripiprazole, a diluent, binder, and water, dried at a temperature less than 70°C, with the wet granulate not milled prior to drying, to prevent hydration and polymorphic transformations, using aripiprazole forms like Type-I, Type-II, or Form II, and incorporating a lubricant like magnesium stearate for improved tablet formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional wet granulation methods are used with aripiprazole anhydride, then granulation can be achieved, but polymorphic transformations occur due to moisture exposure and high drying temperatures (70-100°C)
Solution Approach 1:
The patent changes the drying temperature parameter from the conventional 70-100°C range to a lower range of 25-60°C. This parameter modification prevents polymorphic transformations while still achieving effective granulation and drying, resolving the contradiction between manufacturability and crystal stability
Solution Approach 2:
The patent applies preliminary protective measures by using hygroscopic carriers (such as lactose monoh hydrate or microcrystalline cellulose) that absorb excess moisture during granulation, preventing the aripiprazole from undergoing unwanted polymorphic transformations before the drying step occurs
2Ease of operation
If aripiprazole is exposed to moisture during handling and processing, then handling is simplified, but hygroscopicity causes polymorphic transformations and reduces bioavailability
Solution Approach 1:
The patent introduces hygroscopic carriers as intermediary substances that selectively bind to free moisture in the formulation. These carriers act as mediators between the aripiprazole and environmental moisture, protecting the active ingredient from direct moisture exposure while still allowing the granulation process to proceed effectively
Solution Approach 2:
The patent creates a protected environment during granulation by rapidly drying the wet granulate at low temperatures (25-60°C), effectively creating an inert atmosphere that prevents moisture-induced polymorphic transformations and maintains bioavailability
3Productivity
If high drying temperatures (70-100°C) are used in wet granulation, then drying efficiency is improved, but energy costs increase and polymorphic transformations are induced
Solution Approach 1:
The patent modifies the drying temperature parameter from high (70-100°C) to low (25-60°C), which reduces energy consumption and prevents polymorphic transformations. The use of hygroscopic carriers compensates for the lower temperature by actively absorbing moisture, maintaining drying effectiveness without high energy input
Solution Approach 2:
The patent replaces thermal energy-driven drying with a moisture-absorption mechanism using hygroscopic carriers. This substitution reduces reliance on high-temperature thermal energy while achieving effective moisture removal through the chemical affinity of the carriers for water
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves high dissolution rates of at least 85% of aripiprazole within 30 minutes, with tablets exhibiting excellent flowability and compressibility, reducing energy costs and minimizing polymorphic transformations, while maintaining stability and bioavailability.
Implementation Method 1
drying the wet granulate at a temperature less than 70° C. to obtain a dried granulate
Data Source
AI summary
The invention encompasses wet granulation pharmaceutical compositions of aripiprazole, methods of making tablets from the compositions, and tablets of the wet granulation pharmaceutical composition.